About: Derivation of a novel SARS–coronavirus replicon cell line and its application for anti-SARS drug screening

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Derivation of a novel SARS–coronavirus replicon cell line and its application for anti-SARS drug screening Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Derivation of a novel SARS–coronavirus replicon cell line and its application for anti-SARS drug screening
Creator	Ge, Feng Hung, Eugene Luo, Yonghu Liew, Pei
Source	Elsevier; Medline; PMC
abstract	Abstract The severe acute respiratory syndrome (SARS) outbreak in 2002, which had a high morbidity rate and caused worldwide alarm, remains untreated today even though SARS was eventually isolated and controlled. Development and high-throughput screening of efficacious drugs is therefore critical. However, currently there remains a lack of such a safe system. Here, the generation and characterization of the first selectable, SARS–coronavirus (SARS–CoV)-based replicon cell line which can be used for screening is described. Partial SARS–CoV cDNAs and antibiotic resistance/reporter gene DNA were generated and assembled in vitro to produce the replicon transcription template, which was then transcribed in vitro to generate the replicon RNA. The latter was introduced into a mammalian cell line and the transfected cells were selected for by antibiotic application. For the antibiotic-resistant cell lines thus generated, the expression of reporter gene was ensured by continued monitoring using fluorescent microscopy and flow cytometry. The suitability of this replicon cell line in drug screening was demonstrated by testing the inhibitory effect of several existing drugs and the results demonstrate that the SARS–CoV replicon cell lines provide a safe tool for the identification of SARS–CoV replicase inhibitors. The replicon cell lines thus developed can be applied to high-throughput screening for anti-SARS drugs without the need to grow infectious SARS–CoV.
has issue date	2007-03-30(xsd:dateTime)
bibo:doi	10.1016/j.virol.2006.10.016
bibo:pmid	17098272
has license	els-covid
sha1sum (hex)	e35b885545d471d97431ed31c54f2edd8d4b787d
schema:url	https://doi.org/10.1016/j.virol.2006.10.016
resource representing a document's title	Derivation of a novel SARS–coronavirus replicon cell line and its application for anti-SARS drug screening
has PubMed Central identifier	PMC7103326
has PubMed identifier	17098272
schema:publication	Virology
resource representing a document's body	covid:e35b885545d471d97431ed31c54f2edd8d4b787d#body_text
is schema:about of	named entity 'REPLICON' named entity 'worldwide' named entity 'fluorescent microscopy' named entity 'testing' named entity 'expression' named entity 'selected' named entity 'Derivation' named entity 'CONTINUED' named entity 'HIGH-THROUGHPUT SCREENING' named entity 'PROVIDE' named entity 'WORLDWIDE' named entity 'FLUORESCENT MICROSCOPY' named entity 'INTRODUCED INTO' named entity 'INHIBITORY EFFECT' named entity 'RESULTS' named entity 'INFECTIOUS' named entity 'GENE' named entity 'DNA' named entity 'UNTREATED' named entity 'TO PRODUCE' named entity 'GENERATE' named entity 'ALARM' named entity 'CORONAVIRUS' named entity 'EXPRESSION' named entity 'USING' named entity 'CONTROLLED' named entity 'DEVELOPMENT' named entity 'ANTIBIOTIC' named entity 'SCREENING' named entity 'ISOLATED' named entity 'DRUG SCREENING' named entity 'FLOW CYTOMETRY' named entity 'IN VITRO' named entity 'RNA' named entity 'TRANSCRIBED' named entity 'SELECTED' named entity 'DEMONSTRATED' named entity 'CAUSED' named entity 'CELLS' named entity 'ANTIBIOTIC RESISTANCE' named entity 'TEMPLATE' named entity 'SARS' named entity 'CELL LINE' named entity 'OUTBREAK' named entity 'TOOL' named entity 'SAFE' named entity 'HERE' named entity 'MAMMALIAN CELL' named entity 'RESISTANT CELL' named entity 'TODAY' named entity 'CURRENTLY' named entity 'REPLICASE' named entity 'CELL LINES' named entity 'MONITORING' named entity 'TESTING' named entity 'REPLICON' named entity 'DERIVATION' named entity 'NOVEL' named entity 'CELL LINE' named entity 'DRUG SCREENING' named entity 'ITS' named entity 'CRITICAL' named entity 'CHARACTERIZATION' named entity 'TRANSCRIPTION' named entity 'HIGH' named entity 'MORBIDITY RATE' named entity 'GENERATION' named entity 'BASED' named entity 'GROW' named entity 'SARS-COV' named entity 'NEED' named entity 'PARTIAL' named entity 'LACK' named entity 'DESCRIBED' named entity 'APPLICATION' named entity 'DRUGS' named entity 'SYSTEM' named entity 'REPORTER GENE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software